This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings' Updates: ImClone

ImClone's revenue growth has slightly outpaced the industry average of 1.4%. Over the same quarter a year ago, revenue rose by 10.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.

Compared to where it was trading one year ago, ImClone's share price has jumped by 95.57%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, ImClone should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.

ImClone's earnings per share, or EPS, declined by 19.4% in the most recent quarter compared to a year ago. The company has suffered a pattern of declining EPS over the past two years. However, we anticipate this trend will reverse over the coming year. This year, the market expects an improvement in earnings ($1.21, vs. 45 cents).

ImClone's debt-to-equity ratio of 0.73 is somewhat low overall, but it is high when compared to the industry average, implying that management of the debt levels should be evaluated further.

The change in net income from the same quarter one year ago has exceeded that of the S&P 500 but is less than that of the biotechnology industry average. Net income has decreased by 20.7% when compared to the same quarter one year ago, dropping from $31.91 million to $25.29 million.

ImClone had been rated a hold since Nov. 28, 2007.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $0.35 16.67%
APC $35.68 -4.60%
HURC $23.99 -2.00%
MO $59.98 -0.12%
KYO $38.79 -1.30%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs